Details of the Target

General Information of Target

Target ID LDTP07118
Target Name E3 ubiquitin-protein ligase UBR4 (UBR4)
Gene Name UBR4
Gene ID 23352
Synonyms
KIAA0462; KIAA1307; RBAF600; ZUBR1; E3 ubiquitin-protein ligase UBR4; EC 2.3.2.27; 600 kDa retinoblastoma protein-associated factor; N-recognin-4; RING-type E3 ubiquitin transferase UBR4; Retinoblastoma-associated factor of 600 kDa; RBAF600; p600; Zinc finger UBR1-type protein 1
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MATSGGEEAAAAAPAPGTPATGADTTPGWEVAVRPLLSASYSAFEMKELPQLVASVIESE
SEILHHEKQYEPFYSSFVALSTHYITTVCSLIPRNQLQSVAAACKVLIEFSLLRLENPDE
ACAVSQKHLILLIKGLCTGCSRLDRTEIITFTAMMKSAKLPQTVKTLSDVEDQKELASPV
SPELRQKEVQMNFLNQLTSVFNPRTVASQPISTQTLVEGENDEQSSTDQASAIKTKNVFI
AQNVASLQELGGSEKLLRVCLNLPYFLRYINRFQDAVLANSFFIMPATVADATAVRNGFH
SLVIDVTMALDTLSLPVLEPLNPSRLQDVTVLSLSCLYAGVSVATCMAILHVGSAQQVRT
GSTSSKEDDYESDAATIVQKCLEIYDMIGQAISSSRRAGGEHYQNFQLLGAWCLLNSLFL
ILNLSPTALADKGKEKDPLAALRVRDILSRTKEGVGSPKLGPGKGHQGFGVLSVILANHA
IKLLTSLFQDLQVEALHKGWETDGPPAALSIMAQSTSIQRIQRLIDSVPLMNLLLTLLST
SYRKACVLQRQRKGSMSSDASASTDSNTYYEDDFSSTEEDSSQDDDSEPILGQWFEETIS
PSKEKAAPPPPPPPPPLESSPRVKSPSKQAPGEKGNILASRKDPELFLGLASNILNFITS
SMLNSRNNFIRNYLSVSLSEHHMATLASIIKEVDKDGLKGSSDEEFAAALYHFNHSLVTS
DLQSPNLQNTLLQQLGVAPFSEGPWPLYIHPQSLSVLSRLLLIWQHKASAQGDPDVPECL
KVWDRFLSTMKQNALQGVVPSETEDLNVEHLQMLLLIFHNFTETGRRAILSLFVQIIQEL
SVNMDAQMRFVPLILARLLLIFDYLLHQYSKAPVYLFEQVQHNLLSPPFGWASGSQDSNS
RRATTPLYHGFKEVEENWSKHFSSDAVPHPRFYCVLSPEASEDDLNRLDSVACDVLFSKL
VKYDELYAALTALLAAGSQLDTVRRKENKNVTALEACALQYYFLILWRILGILPPSKTYI
NQLSMNSPEMSECDILHTLRWSSRLRISSYVNWIKDHLIKQGMKAEHASSLLELASTTKC
SSVKYDVEIVEEYFARQISSFCSIDCTTILQLHEIPSLQSIYTLDAAISKVQVSLDEHFS
KMAAETDPHKSSEITKNLLPATLQLIDTYASFTRAYLLQNFNEEGTTEKPSKEKLQGFAA
VLAIGSSRCKANTLGPTLVQNLPSSVQTVCESWNNINTNEFPNIGSWRNAFANDTIPSES
YISAVQAAHLGTLCSQSLPLAASLKHTLLSLVRLTGDLIVWSDEMNPPQVIRTLLPLLLE
SSTESVAEISSNSLERILGPAESDEFLARVYEKLITGCYNILANHADPNSGLDESILEEC
LQYLEKQLESSQARKAMEEFFSDSGELVQIMMATANENLSAKFCNRVLKFFTKLFQLTEK
SPNPSLLHLCGSLAQLACVEPVRLQAWLTRMTTSPPKDSDQLDVIQENRQLLQLLTTYIV
RENSQVGEGVCAVLLGTLTPMATEMLANGDGTGFPELMVVMATLASAGQGAGHLQLHNAA
VDWLSRCKKYLSQKNVVEKLNANVMHGKHVMILECTCHIMSYLADVTNALSQSNGQGPSH
LSVDGEERAIEVDSDWVEELAVEEEDSQAEDSDEDSLCNKLCTFTITQKEFMNQHWYHCH
TCKMVDGVGVCTVCAKVCHKDHEISYAKYGSFFCDCGAKEDGSCLALVKRTPSSGMSSTM
KESAFQSEPRISESLVRHASTSSPADKAKVTISDGKVADEEKPKKSSLCRTVEGCREELQ
NQANFSFAPLVLDMLNFLMDAIQTNFQQASAVGSSSRAQQALSELHTVEKAVEMTDQLMV
PTLGSQEGAFENVRMNYSGDQGQTIRQLISAHVLRRVAMCVLSSPHGRRQHLAVSHEKGK
ITVLQLSALLKQADSSKRKLTLTRLASAPVPFTVLSLTGNPCKEDYLAVCGLKDCHVLTF
SSSGSVSDHLVLHPQLATGNFIIKAVWLPGSQTELAIVTADFVKIYDLCVDALSPTFYFL
LPSSKIRDVTFLFNEEGKNIIVIMSSAGYIYTQLMEEASSAQQGPFYVTNVLEINHEDLK
DSNSQVAGGGVSVYYSHVLQMLFFSYCQGKSFAATISRTTLEVLQLFPINIKSSNGGSKT
SPALCQWSEVMNHPGLVCCVQQTTGVPLVVMVKPDTFLIQEIKTLPAKAKIQDMVAIRHT
ACNEQQRTTMILLCEDGSLRIYMANVENTSYWLQPSLQPSSVISIMKPVRKRKTATITTR
TSSQVTFPIDFFEHNQQLTDVEFGGNDLLQVYNAQQIKHRLNSTGMYVANTKPGGFTIEI
SNNNSTMVMTGMRIQIGTQAIERAPSYIEIFGRTMQLNLSRSRWFDFPFTREEALQADKK
LNLFIGASVDPAGVTMIDAVKIYGKTKEQFGWPDEPPEEFPSASVSNICPSNLNQSNGTG
DSDSAAPTTTSGTVLERLVVSSLEALESCFAVGPIIEKERNKNAAQELATLLLSLPAPAS
VQQQSKSLLASLHTSRSAYHSHKDQALLSKAVQCLNTSSKEGKDLDPEVFQRLVITARSI
AIMRPNNLVHFTESKLPQMETEGMDEGKEPQKQLEGDCCSFITQLVNHFWKLHASKPKNA
FLAPACLPGLTHIEATVNALVDIIHGYCTCELDCINTASKIYMQMLLCPDPAVSFSCKQA
LIRVLRPRNKRRHVTLPSSPRSNTPMGDKDDDDDDDADEKMQSSGIPNGGHIRQESQEQS
EVDHGDFEMVSESMVLETAENVNNGNPSPLEALLAGAEGFPPMLDIPPDADDETMVELAI
ALSLQQDQQGSSSSALGLQSLGLSGQAPSSSSLDAGTLSDTTASAPASDDEGSTAATDGS
TLRTSPADHGGSVGSESGGSAVDSVAGEHSVSGRSSAYGDATAEGHPAGPGSVSSSTGAI
STTTGHQEGDGSEGEGEGETEGDVHTSNRLHMVRLMLLERLLQTLPQLRNVGGVRAIPYM
QVILMLTTDLDGEDEKDKGALDNLLSQLIAELGMDKKDVSKKNERSALNEVHLVVMRLLS
VFMSRTKSGSKSSICESSSLISSATAAALLSSGAVDYCLHVLKSLLEYWKSQQNDEEPVA
TSQLLKPHTTSSPPDMSPFFLRQYVKGHAADVFEAYTQLLTEMVLRLPYQIKKITDTNSR
IPPPVFDHSWFYFLSEYLMIQQTPFVRRQVRKLLLFICGSKEKYRQLRDLHTLDSHVRGI
KKLLEEQGIFLRASVVTASSGSALQYDTLISLMEHLKACAEIAAQRTINWQKFCIKDDSV
LYFLLQVSFLVDEGVSPVLLQLLSCALCGSKVLAALAASSGSSSASSSSAPVAASSGQAT
TQSKSSTKKSKKEEKEKEKDGETSGSQEDQLCTALVNQLNKFADKETLIQFLRCFLLESN
SSSVRWQAHCLTLHIYRNSSKSQQELLLDLMWSIWPELPAYGRKAAQFVDLLGYFSLKTP
QTEKKLKEYSQKAVEILRTQNHILTNHPNSNIYNTLSGLVEFDGYYLESDPCLVCNNPEV
PFCYIKLSSIKVDTRYTTTQQVVKLIGSHTISKVTVKIGDLKRTKMVRTINLYYNNRTVQ
AIVELKNKPARWHKAKKVQLTPGQTEVKIDLPLPIVASNLMIEFADFYENYQASTETLQC
PRCSASVPANPGVCGNCGENVYQCHKCRSINYDEKDPFLCNACGFCKYARFDFMLYAKPC
CAVDPIENEEDRKKAVSNINTLLDKADRVYHQLMGHRPQLENLLCKVNEAAPEKPQDDSG
TAGGISSTSASVNRYILQLAQEYCGDCKNSFDELSKIIQKVFASRKELLEYDLQQREAAT
KSSRTSVQPTFTASQYRALSVLGCGHTSSTKCYGCASAVTEHCITLLRALATNPALRHIL
VSQGLIRELFDYNLRRGAAAMREEVRQLMCLLTRDNPEATQQMNDLIIGKVSTALKGHWA
NPDLASSLQYEMLLLTDSISKEDSCWELRLRCALSLFLMAVNIKTPVVVENITLMCLRIL
QKLIKPPAPTSKKNKDVPVEALTTVKPYCNEIHAQAQLWLKRDPKASYDAWKKCLPIRGI
DGNGKAPSKSELRHLYLTEKYVWRWKQFLSRRGKRTSPLDLKLGHNNWLRQVLFTPATQA
ARQAACTIVEALATIPSRKQQVLDLLTSYLDELSIAGECAAEYLALYQKLITSAHWKVYL
AARGVLPYVGNLITKEIARLLALEEATLSTDLQQGYALKSLTGLLSSFVEVESIKRHFKS
RLVGTVLNGYLCLRKLVVQRTKLIDETQDMLLEMLEDMTTGTESETKAFMAVCIETAKRY
NLDDYRTPVFIFERLCSIIYPEENEVTEFFVTLEKDPQQEDFLQGRMPGNPYSSNEPGIG
PLMRDIKNKICQDCDLVALLEDDSGMELLVNNKIISLDLPVAEVYKKVWCTTNEGEPMRI
VYRMRGLLGDATEEFIESLDSTTDEEEDEEEVYKMAGVMAQCGGLECMLNRLAGIRDFKQ
GRHLLTVLLKLFSYCVKVKVNRQQLVKLEMNTLNVMLGTLNLALVAEQESKDSGGAAVAE
QVLSIMEIILDESNAEPLSEDKGNLLLTGDKDQLVMLLDQINSTFVRSNPSVLQGLLRII
PYLSFGEVEKMQILVERFKPYCNFDKYDEDHSGDDKVFLDCFCKIAAGIKNNSNGHQLKD
LILQKGITQNALDYMKKHIPSAKNLDADIWKKFLSRPALPFILRLLRGLAIQHPGTQVLI
GTDSIPNLHKLEQVSSDEGIGTLAENLLEALREHPDVNKKIDAARRETRAEKKRMAMAMR
QKALGTLGMTTNEKGQVVTKTALLKQMEELIEEPGLTCCICREGYKFQPTKVLGIYTFTK
RVALEEMENKPRKQQGYSTVSHFNIVHYDCHLAAVRLARGREEWESAALQNANTKCNGLL
PVWGPHVPESAFATCLARHNTYLQECTGQREPTYQLNIHDIKLLFLRFAMEQSFSADTGG
GGRESNIHLIPYIIHTVLYVLNTTRATSREEKNLQGFLEQPKEKWVESAFEVDGPYYFTV
LALHILPPEQWRATRVEILRRLLVTSQARAVAPGGATRLTDKAVKDYSAYRSSLLFWALV
DLIYNMFKKVPTSNTEGGWSCSLAEYIRHNDMPIYEAADKALKTFQEEFMPVETFSEFLD
VAGLLSEITDPESFLKDLLNSVP
Target Bioclass
Enzyme
Family
UBR4 family
Subcellular location
Membrane
Function
E3 ubiquitin-protein ligase which is a component of the N-end rule pathway. Recognizes and binds to proteins bearing specific N-terminal residues that are destabilizing according to the N-end rule, leading to their ubiquitination and subsequent degradation. Together with clathrin, forms meshwork structures involved in membrane morphogenesis and cytoskeletal organization. Regulates integrin-mediated signaling. May play a role in activation of FAK in response to cell-matrix interactions. Mediates ubiquitination of ACLY, leading to its subsequent degradation.
Uniprot ID
Q5T4S7
Ensemble ID
ENST00000375218.3
HGNC ID
HGNC:30313
ChEMBL ID
CHEMBL4295851

Target Site Mutations in Different Cell Lines

Cell line Mutation details Probe for labeling this protein in this cell
A172 Insertion: p.T3598_V3599insGT DBIA    Probe Info 
A431 SNV: p.M4809I DBIA    Probe Info 
CCK81 SNV: p.H1892R; p.T2534I; p.K5140N DBIA    Probe Info 
CCSW1 SNV: p.L2119W DBIA    Probe Info 
COLO792 SNV: p.S1224L; p.A1695D DBIA    Probe Info 
EFO27 Deletion: p.M2803CfsTer16 DBIA    Probe Info 
FADU SNV: p.E3313K DBIA    Probe Info 
HCT116 Deletion: p.M2803CfsTer16
SNV: p.Q4600Ter		 .
HCT15 SNV: p.D169Y DBIA    Probe Info 
HEC1 SNV: p.K1769N DBIA    Probe Info 
HEC1B SNV: p.Q3848Ter IA-alkyne    Probe Info 
HT115 SNV: p.R2270Ter; p.D2854G; p.A3338T DBIA    Probe Info 
HUH28 Deletion: p.P2494QfsTer55
SNV: p.F1805L		 DBIA    Probe Info 
HUPT4 SNV: p.Y4442S DBIA    Probe Info 
ICC9 SNV: p.G2109D DBIA    Probe Info 
Ishikawa (Heraklio) 02 ER SNV: p.F1094L DBIA    Probe Info 
MCC13 SNV: p.P2288S DBIA    Probe Info 
MFE319 SNV: p.P1279S; p.R4115S DBIA    Probe Info 
MOLT4 SNV: p.A2005V; p.Q3903Ter IA-alkyne    Probe Info 
NCIH1299 SNV: p.V5152L m-APA    Probe Info 
NCIH1666 SNV: p.A158S DBIA    Probe Info 
NCIH1792 SNV: p.K3041R DBIA    Probe Info 
NCIH1793 SNV: p.Y4442S DBIA    Probe Info 
NCIH2122 Deletion: p.I4386KfsTer9 DBIA    Probe Info 
NCIH446 SNV: p.K1963E DBIA    Probe Info 
NUGC3 SNV: p.S4975N DBIA    Probe Info 
RD SNV: p.S3978F DBIA    Probe Info 
RL952 SNV: p.M2583I; p.V4895I DBIA    Probe Info 
SHP77 SNV: p.I4254M DBIA    Probe Info 
SISO SNV: p.D2888N DBIA    Probe Info 
SKMEL24 SNV: p.T2196S DBIA    Probe Info 
SNGM Deletion: p.G4555VfsTer16
SNV: p.S4579G		 DBIA    Probe Info 
SNU1 SNV: p.R3989Q DBIA    Probe Info 
SNU308 SNV: p.T2861A DBIA    Probe Info 
SUPT1 SNV: p.S581G DBIA    Probe Info 
SW837 SNV: p.S1786T DBIA    Probe Info 
SW948 SNV: p.Y2126C DBIA    Probe Info 
TE11 SNV: p.C2165R; p.P3508S DBIA    Probe Info 
U87MG Deletion: p.S3356LfsTer41 DBIA    Probe Info 

Probe(s) Labeling This Target

ABPP Probe
Click To Hide/Show 37 Probe Related to This Target
Probe name Structure Binding Site(Ratio) Interaction ID Ref
m-APA
 Probe Info  		9.57  LDD0402  [1]
A-EBA
 Probe Info  		3.36  LDD0215  [2]
CY-1
 Probe Info  		100.00  LDD0243  [3]
CY4
 Probe Info  		100.00  LDD0244  [3]
N1
 Probe Info  		100.00  LDD0242  [3]
TH211
 Probe Info  		Y4622(9.28)  LDD0260  [4]
STPyne
 Probe Info  		K2636(1.89); K3617(10.00); K3745(0.17); K3820(5.85)  LDD0277  [5]
ONAyne
 Probe Info  		K1150(1.43)  LDD0275  [5]
Probe 1
 Probe Info  		Y370(11.13); Y3169(16.05); Y3831(16.25); Y4199(17.01)  LDD3495  [6]
BTD
 Probe Info  		C3864(2.00); C546(1.01)  LDD1700  [7]
DA-P3
 Probe Info  		13.85  LDD0183  [8]
AHL-Pu-1
 Probe Info  		C3864(2.11); C2554(3.10); C2222(2.22); C1458(2.62)  LDD0168  [9]
DBIA
 Probe Info  		C1033(32.95); C4663(10.44); C2554(4.97); C2222(160.05)  LDD0209  [10]
HHS-482
 Probe Info  		Y3474(0.52)  LDD0285  [11]
HHS-475
 Probe Info  		Y5135(0.90); Y3474(0.96)  LDD0264  [12]
ATP probe
 Probe Info  		K3573(0.00); K2399(0.00); K2400(0.00); K3745(0.00)  LDD0199  [13]
4-Iodoacetamidophenylacetylene
 Probe Info  		C3864(0.00); C1230(0.00); C2554(0.00); C3414(0.00)  LDD0038  [14]
IA-alkyne
 Probe Info  		N.A.  LDD0032  [15]
IPIAA_H
 Probe Info  		N.A.  LDD0030  [16]
IPIAA_L
 Probe Info  		C1274(0.00); C4336(0.00)  LDD0031  [16]
Lodoacetamide azide
 Probe Info  		C3279(0.00); C4313(0.00); C1230(0.00); C2554(0.00)  LDD0037  [14]
ATP probe
 Probe Info  		N.A.  LDD0035  [17]
NAIA_4
 Probe Info  		C2222(0.00); C2554(0.00); C3864(0.00); C4946(0.00)  LDD2226  [18]
TFBX
 Probe Info  		C104(0.00); C2554(0.00)  LDD0027  [19]
WYneN
 Probe Info  		C779(0.00); C122(0.00); C2222(0.00)  LDD0021  [20]
WYneO
 Probe Info  		N.A.  LDD0022  [20]
Compound 10
 Probe Info  		C2222(0.00); C2554(0.00)  LDD2216  [21]
Compound 11
 Probe Info  		C2222(0.00); C2554(0.00)  LDD2213  [21]
IPM
 Probe Info  		C2554(0.00); C3864(0.00)  LDD0005  [20]
1c-yne
 Probe Info  		K4802(0.00); K236(0.00)  LDD0228  [22]
1d-yne
 Probe Info  		N.A.  LDD0357  [22]
Acrolein
 Probe Info  		C4946(0.00); C953(0.00); C3864(0.00); C122(0.00)  LDD0217  [23]
Methacrolein
 Probe Info  		C3864(0.00); C2222(0.00); C4946(0.00)  LDD0218  [23]
W1
 Probe Info  		C2554(0.00); C4946(0.00); C122(0.00); C4661(0.00)  LDD0236  [24]
AOyne
 Probe Info  		4.80  LDD0443  [25]
NAIA_5
 Probe Info  		C3864(0.00); C2554(0.00); C4074(0.00); C1724(0.00)  LDD2223  [18]
HHS-465
 Probe Info  		Y3474(0.00); K3478(0.00)  LDD2240  [26]
PAL-AfBPP Probe
Click To Hide/Show 2 Probe Related to This Target
Probe name Structure Binding Site(Ratio) Interaction ID Ref
STS-1
 Probe Info  		N.A.  LDD0137  [27]
STS-2
 Probe Info  		N.A.  LDD0138  [27]

Competitor(s) Related to This Target

Competitor ID Name Cell line Binding Site(Ratio) Interaction ID Ref
 LDCM0537  2-Cyano-N,N-dimethylacetamide MDA-MB-231 C2554(0.56)  LDD2130  [7]
 LDCM0524  2-Cyano-N-(2-morpholin-4-yl-ethyl)-acetamide MDA-MB-231 C546(0.83); C1900(0.91); C1795(1.05)  LDD2117  [7]
 LDCM0558  2-Cyano-N-phenylacetamide MDA-MB-231 C3864(0.92); C546(1.37)  LDD2152  [7]
 LDCM0510  3-(4-(Hydroxydiphenylmethyl)piperidin-1-yl)-3-oxopropanenitrile MDA-MB-231 C546(1.03)  LDD2103  [7]
 LDCM0539  3-(4-Isopropylpiperazin-1-yl)-3-oxopropanenitrile MDA-MB-231 C546(0.82); C1900(0.75)  LDD2132  [7]
 LDCM0025  4SU-RNA HEK-293T C3864(2.11); C2554(3.10); C2222(2.22); C1458(2.62)  LDD0168  [9]
 LDCM0026  4SU-RNA+native RNA HEK-293T C3864(4.14); C2554(3.88); C2222(2.83); C1458(3.16)  LDD0169  [9]
 LDCM0545  Acetamide MDA-MB-231 C546(0.30); C1900(0.48)  LDD2138  [7]
 LDCM0520  AKOS000195272 MDA-MB-231 C546(0.87)  LDD2113  [7]
 LDCM0156  Aniline NCI-H1299 N.A.  LDD0405  [1]
 LDCM0498  BS-3668 MDA-MB-231 C2222(0.43)  LDD2091  [7]
 LDCM0108  Chloroacetamide HeLa C953(0.00); C4146(0.00); C4946(0.00); C4430(0.00)  LDD0222  [23]
 LDCM0632  CL-Sc Hep-G2 C2554(20.00); C4916(20.00); C1274(3.13); C3218(1.01)  LDD2227  [18]
 LDCM0634  CY-0357 Hep-G2 C122(3.07); C2554(1.52); C2222(1.12); C3864(0.66)  LDD2228  [18]
 LDCM0213  Electrophilic fragment 2 MDA-MB-231 C140(8.25); C4515(3.95); C3864(3.95); C4642(2.63)  LDD1702  [7]
 LDCM0031  Epigallocatechin gallate HEK-293T 13.85  LDD0183  [8]
 LDCM0625  F8 Ramos C2222(1.58); C546(1.01); 1.25; C3279(1.06)  LDD2187  [28]
 LDCM0572  Fragment10 Ramos C2222(2.57); C546(1.62); C3279(1.01); C2554(2.52)  LDD2189  [28]
 LDCM0573  Fragment11 Ramos C2222(1.81); C546(2.65); C3279(2.28); C2554(2.63)  LDD2190  [28]
 LDCM0574  Fragment12 Ramos C2222(1.73); C546(2.02); C3279(0.98); C2554(1.64)  LDD2191  [28]
 LDCM0575  Fragment13 Ramos C2222(1.11); C546(1.14); C3279(1.00); C2554(0.75)  LDD2192  [28]
 LDCM0576  Fragment14 Ramos C2222(0.97); C546(1.66); 1.36; C2554(1.29)  LDD2193  [28]
 LDCM0579  Fragment20 Ramos C2222(3.18); C3279(1.12); C2554(0.99); C104(0.71)  LDD2194  [28]
 LDCM0580  Fragment21 Ramos C2222(1.43); C546(1.13); C3279(1.22); C2554(1.00)  LDD2195  [28]
 LDCM0582  Fragment23 Ramos C2222(0.69); C546(0.97); C3279(1.26); C2554(1.72)  LDD2196  [28]
 LDCM0578  Fragment27 Ramos C2222(1.47); C546(0.90); C3279(0.91); C2554(0.96)  LDD2197  [28]
 LDCM0586  Fragment28 Ramos C2222(0.56); C546(0.57); 1.02; C2554(0.39)  LDD2198  [28]
 LDCM0588  Fragment30 Ramos C2222(1.73); C546(1.21); C3279(2.36); C2554(1.16)  LDD2199  [28]
 LDCM0589  Fragment31 Ramos C2222(1.12); C546(0.90); C3279(1.30); C2554(1.03)  LDD2200  [28]
 LDCM0590  Fragment32 Ramos C2222(2.53); C546(1.96); C3279(0.82); C2554(1.26)  LDD2201  [28]
 LDCM0468  Fragment33 Ramos C2222(1.45); C546(1.21); C3279(1.06); C2554(0.93)  LDD2202  [28]
 LDCM0596  Fragment38 Ramos C2222(1.37); C546(1.36); C3279(1.06); C2554(1.17)  LDD2203  [28]
 LDCM0566  Fragment4 Ramos C2222(0.94); C546(1.47); C3279(0.96); C2554(0.87)  LDD2184  [28]
 LDCM0610  Fragment52 Ramos C2222(2.08); C546(1.28); C2554(1.34); C104(1.51)  LDD2204  [28]
 LDCM0614  Fragment56 Ramos C2222(1.77); C546(1.14); C3279(1.74); C2554(1.34)  LDD2205  [28]
 LDCM0569  Fragment7 Ramos C2222(1.77); C546(1.52); 0.95; C3279(0.96)  LDD2186  [28]
 LDCM0571  Fragment9 Ramos C2222(3.41); C546(2.00); C3279(1.16); C2554(1.41)  LDD2188  [28]
 LDCM0116  HHS-0101 DM93 Y5135(0.90); Y3474(0.96)  LDD0264  [12]
 LDCM0117  HHS-0201 DM93 Y3474(0.90); Y5135(1.41)  LDD0265  [12]
 LDCM0118  HHS-0301 DM93 Y3474(0.77); Y5135(1.40)  LDD0266  [12]
 LDCM0119  HHS-0401 DM93 Y3474(0.90); Y5135(1.72)  LDD0267  [12]
 LDCM0120  HHS-0701 DM93 Y3474(0.98); Y5135(1.89)  LDD0268  [12]
 LDCM0107  IAA HeLa C953(0.00); H3231(0.00); C4313(0.00); C934(0.00)  LDD0221  [23]
 LDCM0123  JWB131 DM93 Y3474(0.52)  LDD0285  [11]
 LDCM0124  JWB142 DM93 Y3474(0.26)  LDD0286  [11]
 LDCM0125  JWB146 DM93 Y3474(1.13)  LDD0287  [11]
 LDCM0126  JWB150 DM93 Y3474(11.42)  LDD0288  [11]
 LDCM0128  JWB198 DM93 Y3474(1.28)  LDD0290  [11]
 LDCM0129  JWB202 DM93 Y3474(0.43)  LDD0291  [11]
 LDCM0130  JWB211 DM93 Y3474(0.80)  LDD0292  [11]
 LDCM0022  KB02 HEK-293T C2222(0.91); C2554(1.01); C104(0.86); C122(0.93)  LDD1492  [29]
 LDCM0023  KB03 Jurkat C1033(32.95); C4663(10.44); C2554(4.97); C2222(160.05)  LDD0209  [10]
 LDCM0024  KB05 G361 C3279(2.44); C2223(1.75); C2029(1.21); C4146(2.47)  LDD3311  [30]
 LDCM0528  N-(4-bromophenyl)-2-cyano-N-phenylacetamide MDA-MB-231 C1900(0.83)  LDD2121  [7]
 LDCM0109  NEM HeLa H5129(0.00); H4094(0.00); H3236(0.00); H3231(0.00)  LDD0224  [23]
 LDCM0496  Nucleophilic fragment 11a MDA-MB-231 C2554(0.79)  LDD2089  [7]
 LDCM0497  Nucleophilic fragment 11b MDA-MB-231 C2554(2.54)  LDD2090  [7]
 LDCM0499  Nucleophilic fragment 12b MDA-MB-231 C2222(0.84)  LDD2092  [7]
 LDCM0500  Nucleophilic fragment 13a MDA-MB-231 C3864(0.80); C546(0.96); C1900(1.63); C104(0.99)  LDD2093  [7]
 LDCM0501  Nucleophilic fragment 13b MDA-MB-231 C546(1.40); C2222(1.16); C1080(0.95)  LDD2094  [7]
 LDCM0503  Nucleophilic fragment 14b MDA-MB-231 C546(0.36)  LDD2096  [7]
 LDCM0505  Nucleophilic fragment 15b MDA-MB-231 C546(0.75); C2222(0.90); C1080(0.62)  LDD2098  [7]
 LDCM0506  Nucleophilic fragment 16a MDA-MB-231 C546(0.99); C2554(0.75); C1900(1.09); C3279(1.17)  LDD2099  [7]
 LDCM0508  Nucleophilic fragment 17a MDA-MB-231 C3279(0.34)  LDD2101  [7]
 LDCM0511  Nucleophilic fragment 18b MDA-MB-231 C4946(0.77)  LDD2104  [7]
 LDCM0512  Nucleophilic fragment 19a MDA-MB-231 C2222(1.18)  LDD2105  [7]
 LDCM0514  Nucleophilic fragment 20a MDA-MB-231 C1900(1.21); C3279(1.26); C1795(1.47)  LDD2107  [7]
 LDCM0516  Nucleophilic fragment 21a MDA-MB-231 C546(0.60); C2554(0.52); C3279(0.41)  LDD2109  [7]
 LDCM0518  Nucleophilic fragment 22a MDA-MB-231 C3864(0.81); C546(0.96); C2554(0.98); C1900(1.71)  LDD2111  [7]
 LDCM0523  Nucleophilic fragment 24b MDA-MB-231 C546(0.80)  LDD2116  [7]
 LDCM0525  Nucleophilic fragment 25b MDA-MB-231 C104(0.38)  LDD2118  [7]
 LDCM0526  Nucleophilic fragment 26a MDA-MB-231 C546(2.44); C1900(1.35)  LDD2119  [7]
 LDCM0529  Nucleophilic fragment 27b MDA-MB-231 C104(0.18)  LDD2122  [7]
 LDCM0530  Nucleophilic fragment 28a MDA-MB-231 C4642(1.35)  LDD2123  [7]
 LDCM0531  Nucleophilic fragment 28b MDA-MB-231 C2554(0.53); C104(0.21)  LDD2124  [7]
 LDCM0532  Nucleophilic fragment 29a MDA-MB-231 C2554(0.52); C3279(0.70); C779(1.19)  LDD2125  [7]
 LDCM0533  Nucleophilic fragment 29b MDA-MB-231 C104(0.35)  LDD2126  [7]
 LDCM0534  Nucleophilic fragment 30a MDA-MB-231 C546(0.89)  LDD2127  [7]
 LDCM0536  Nucleophilic fragment 31 MDA-MB-231 C3864(0.92); C546(0.86)  LDD2129  [7]
 LDCM0540  Nucleophilic fragment 35 MDA-MB-231 C3279(0.41)  LDD2133  [7]
 LDCM0542  Nucleophilic fragment 37 MDA-MB-231 C546(0.86)  LDD2135  [7]
 LDCM0543  Nucleophilic fragment 38 MDA-MB-231 C2554(1.05); C3279(1.95)  LDD2136  [7]
 LDCM0544  Nucleophilic fragment 39 MDA-MB-231 C546(0.88); C2554(0.99); C1900(1.25); C1795(1.47)  LDD2137  [7]
 LDCM0211  Nucleophilic fragment 3b MDA-MB-231 C3864(2.00); C546(1.01)  LDD1700  [7]
 LDCM0546  Nucleophilic fragment 40 MDA-MB-231 C546(0.67); C1900(1.15); C104(0.79); C3279(1.22)  LDD2140  [7]
 LDCM0547  Nucleophilic fragment 41 MDA-MB-231 C1080(0.52)  LDD2141  [7]
 LDCM0550  Nucleophilic fragment 5a MDA-MB-231 C546(3.02); C4642(1.61)  LDD2144  [7]
 LDCM0552  Nucleophilic fragment 6a MDA-MB-231 C3864(1.09); C546(0.71); C2554(0.71); C1900(1.37)  LDD2146  [7]
 LDCM0554  Nucleophilic fragment 7a MDA-MB-231 C3279(0.64); C1795(0.51)  LDD2148  [7]
 LDCM0556  Nucleophilic fragment 8a MDA-MB-231 C546(0.36); C1900(1.21); C2222(1.50)  LDD2150  [7]
 LDCM0559  Nucleophilic fragment 9b MDA-MB-231 C2554(1.26)  LDD2153  [7]
 LDCM0032  Oleacein HEK-293T 5.15  LDD0184  [8]
 LDCM0628  OTUB2-COV-1 HEK-293T C2222(0.50)  LDD2207  [31]
 LDCM0112  W16 Hep-G2 C2222(0.79)  LDD0239  [24]

The Interaction Atlas With This Target

The Protein(s) Related To This Target

Enzyme
Click To Hide/Show 1 Protein(s) Interacting with This Target
Protein name Family Uniprot ID
Ubiquitin carboxyl-terminal hydrolase 7 (USP7) Peptidase C19 family Q93009
Other
Click To Hide/Show 1 Protein(s) Interacting with This Target
Protein name Family Uniprot ID
Sprouty-related, EVH1 domain-containing protein 1 (SPRED1) . Q7Z699

The Drug(s) Related To This Target

Investigative
Click To Hide/Show 2 Drug(s) Interacting with This Target
Drug Name Drug Type External ID
Verpasep Caltespen Vaccine DB04959
Picolinic Acid . DB05483

References

1 Quantitative and Site-Specific Chemoproteomic Profiling of Targets of Acrolein. Chem Res Toxicol. 2019 Mar 18;32(3):467-473. doi: 10.1021/acs.chemrestox.8b00343. Epub 2019 Jan 15.
2 2-Ethynylbenzaldehyde-Based, Lysine-Targeting Irreversible Covalent Inhibitors for Protein Kinases and Nonkinases. J Am Chem Soc. 2023 Feb 12. doi: 10.1021/jacs.2c11595. Online ahead of print.
Mass spectrometry data entry: PXD037665
3 Cyclopropenone, Cyclopropeniminium Ion, and Cyclopropenethione as Novel Electrophilic Warheads for Potential Target Discovery of Triple-Negative Breast Cancer. J Med Chem. 2023 Feb 23;66(4):2851-2864. doi: 10.1021/acs.jmedchem.2c01889. Epub 2023 Feb 10.
4 Chemoproteomic profiling of kinases in live cells using electrophilic sulfonyl triazole probes. Chem Sci. 2021 Jan 21;12(9):3295-3307. doi: 10.1039/d0sc06623k.
5 A Paal-Knorr agent for chemoproteomic profiling of targets of isoketals in cells. Chem Sci. 2021 Oct 15;12(43):14557-14563. doi: 10.1039/d1sc02230j. eCollection 2021 Nov 10.
Mass spectrometry data entry: PXD028270
6 An Azo Coupling-Based Chemoproteomic Approach to Systematically Profile the Tyrosine Reactivity in the Human Proteome. Anal Chem. 2021 Jul 27;93(29):10334-10342. doi: 10.1021/acs.analchem.1c01935. Epub 2021 Jul 12.
7 Nucleophilic covalent ligand discovery for the cysteine redoxome. Nat Chem Biol. 2023 Nov;19(11):1309-1319. doi: 10.1038/s41589-023-01330-5. Epub 2023 May 29.
Mass spectrometry data entry: PXD039908 , PXD029761
8 A chemical probe unravels the reactive proteome of health-associated catechols. Chem Sci. 2023 Jul 22;14(32):8635-8643. doi: 10.1039/d3sc00888f. eCollection 2023 Aug 16.
Mass spectrometry data entry: PXD043348
9 Chemoproteomic capture of RNA binding activity in living cells. Nat Commun. 2023 Oct 7;14(1):6282. doi: 10.1038/s41467-023-41844-z.
Mass spectrometry data entry: PXD044625
10 Covalent Inhibition by a Natural Product-Inspired Latent Electrophile. J Am Chem Soc. 2023 May 24;145(20):11097-11109. doi: 10.1021/jacs.3c00598. Epub 2023 May 15.
11 Chemoproteomic profiling of kinases in live cells using electrophilic sulfonyl triazole probes. Chem Sci. 2021 Jan 21;12(9):3295-3307. doi: 10.1039/d0sc06623k.
12 Discovery of a Cell-Active SuTEx Ligand of Prostaglandin Reductase 2. Chembiochem. 2021 Jun 15;22(12):2134-2139. doi: 10.1002/cbic.202000879. Epub 2021 Apr 29.
13 Targeted Proteomic Approaches for Proteome-Wide Characterizations of the AMP-Binding Capacities of Kinases. J Proteome Res. 2022 Aug 5;21(8):2063-2070. doi: 10.1021/acs.jproteome.2c00225. Epub 2022 Jul 12.
14 Enhancing Cysteine Chemoproteomic Coverage through Systematic Assessment of Click Chemistry Product Fragmentation. Anal Chem. 2022 Mar 8;94(9):3800-3810. doi: 10.1021/acs.analchem.1c04402. Epub 2022 Feb 23.
Mass spectrometry data entry: PXD028853
15 SP3-FAIMS Chemoproteomics for High-Coverage Profiling of the Human Cysteinome*. Chembiochem. 2021 May 14;22(10):1841-1851. doi: 10.1002/cbic.202000870. Epub 2021 Feb 18.
Mass spectrometry data entry: PXD023056 , PXD023059 , PXD023058 , PXD023057 , PXD023060
16 SP3-Enabled Rapid and High Coverage Chemoproteomic Identification of Cell-State-Dependent Redox-Sensitive Cysteines. Mol Cell Proteomics. 2022 Apr;21(4):100218. doi: 10.1016/j.mcpro.2022.100218. Epub 2022 Feb 25.
Mass spectrometry data entry: PXD029500 , PXD031647
17 Comparison of Quantitative Mass Spectrometry Platforms for Monitoring Kinase ATP Probe Uptake in Lung Cancer. J Proteome Res. 2018 Jan 5;17(1):63-75. doi: 10.1021/acs.jproteome.7b00329. Epub 2017 Nov 22.
Mass spectrometry data entry: PXD006095 , PXD006096
18 N-Acryloylindole-alkyne (NAIA) enables imaging and profiling new ligandable cysteines and oxidized thiols by chemoproteomics. Nat Commun. 2023 Jun 15;14(1):3564. doi: 10.1038/s41467-023-39268-w.
Mass spectrometry data entry: PXD041264
19 Chemoproteomic Profiling by Cysteine Fluoroalkylation Reveals Myrocin G as an Inhibitor of the Nonhomologous End Joining DNA Repair Pathway. J Am Chem Soc. 2021 Dec 8;143(48):20332-20342. doi: 10.1021/jacs.1c09724. Epub 2021 Nov 24.
Mass spectrometry data entry: PXD029255
20 A modification-centric assessment tool for the performance of chemoproteomic probes. Nat Chem Biol. 2022 Aug;18(8):904-912. doi: 10.1038/s41589-022-01074-8. Epub 2022 Jul 21.
Mass spectrometry data entry: PXD027758 , PXD027755 , PXD027760 , PXD027762 , PXD027756 , PXD027591 , PXD007149 , PXD030064 , PXD032392 , PXD027789 , PXD027767 , PXD027764
21 Multiplexed CuAAC Suzuki-Miyaura Labeling for Tandem Activity-Based Chemoproteomic Profiling. Anal Chem. 2021 Feb 2;93(4):2610-2618. doi: 10.1021/acs.analchem.0c04726. Epub 2021 Jan 20.
Mass spectrometry data entry: PXD022279
22 Tunable Amine-Reactive Electrophiles for Selective Profiling of Lysine. Angew Chem Int Ed Engl. 2022 Jan 26;61(5):e202112107. doi: 10.1002/anie.202112107. Epub 2021 Dec 16.
23 ACR-Based Probe for the Quantitative Profiling of Histidine Reactivity in the Human Proteome. J Am Chem Soc. 2023 Mar 8;145(9):5252-5260. doi: 10.1021/jacs.2c12653. Epub 2023 Feb 27.
24 Oxidant-Induced Bioconjugation for Protein Labeling in Live Cells. ACS Chem Biol. 2023 Jan 20;18(1):112-122. doi: 10.1021/acschembio.2c00740. Epub 2022 Dec 21.
25 Chemoproteomic profiling of targets of lipid-derived electrophiles by bioorthogonal aminooxy probe. Redox Biol. 2017 Aug;12:712-718. doi: 10.1016/j.redox.2017.04.001. Epub 2017 Apr 5.
26 Global profiling identifies a stress-responsive tyrosine site on EDC3 regulating biomolecular condensate formation. Cell Chem Biol. 2022 Dec 15;29(12):1709-1720.e7. doi: 10.1016/j.chembiol.2022.11.008. Epub 2022 Dec 6.
Mass spectrometry data entry: PXD038010
27 Design and synthesis of minimalist terminal alkyne-containing diazirine photo-crosslinkers and their incorporation into kinase inhibitors for cell- and tissue-based proteome profiling. Angew Chem Int Ed Engl. 2013 Aug 12;52(33):8551-6. doi: 10.1002/anie.201300683. Epub 2013 Jun 10.
28 Site-specific quantitative cysteine profiling with data-independent acquisition-based mass spectrometry. Methods Enzymol. 2023;679:295-322. doi: 10.1016/bs.mie.2022.07.037. Epub 2022 Sep 7.
Mass spectrometry data entry: PXD027578
29 Accelerating multiplexed profiling of protein-ligand interactions: High-throughput plate-based reactive cysteine profiling with minimal input. Cell Chem Biol. 2024 Mar 21;31(3):565-576.e4. doi: 10.1016/j.chembiol.2023.11.015. Epub 2023 Dec 19.
Mass spectrometry data entry: PXD044402
30 DrugMap: A quantitative pan-cancer analysis of cysteine ligandability. Cell. 2024 May 9;187(10):2536-2556.e30. doi: 10.1016/j.cell.2024.03.027. Epub 2024 Apr 22.
Mass spectrometry data entry: PXD047840
31 Rapid Covalent-Probe Discovery by Electrophile-Fragment Screening. J Am Chem Soc. 2019 Jun 5;141(22):8951-8968. doi: 10.1021/jacs.9b02822. Epub 2019 May 22.